Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price traded up 6.6% on Monday . The company traded as high as $9.88 and last traded at $9.70. 9,227 shares changed hands during trading, an increase of 76% from the average session volume of 5,245 shares. The stock had previously closed at $9.10.
Analyst Upgrades and Downgrades
PHAR has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and set a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th. Oppenheimer decreased their target price on Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, October 28th. Finally, Jefferies Financial Group initiated coverage on Pharming Group in a research report on Monday, December 9th. They issued a "buy" rating and a $14.00 price target on the stock.
Get Our Latest Analysis on PHAR
Pharming Group Price Performance
The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The stock's 50-day moving average price is $8.30 and its 200 day moving average price is $8.14. The firm has a market cap of $707.52 million, a price-to-earnings ratio of -40.12 and a beta of 0.05.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,110 shares of the company's stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
